BE1029004B1 - New pharmaceutical formulations, based on simple metabolites, for use in degenerative disorders of the nervous system, in viral infections and in tumor diseases - Google Patents

New pharmaceutical formulations, based on simple metabolites, for use in degenerative disorders of the nervous system, in viral infections and in tumor diseases

Info

Publication number
BE1029004B1
BE1029004B1 BE20210007A BE202100007A BE1029004B1 BE 1029004 B1 BE1029004 B1 BE 1029004B1 BE 20210007 A BE20210007 A BE 20210007A BE 202100007 A BE202100007 A BE 202100007A BE 1029004 B1 BE1029004 B1 BE 1029004B1
Authority
BE
Belgium
Prior art keywords
pharmaceutical formulations
nervous system
degenerative disorders
glucosamine
viral infections
Prior art date
Application number
BE20210007A
Other languages
Dutch (nl)
Other versions
BE1029004A1 (en
Inventor
Canipa René Delgadillo
Original Assignee
Kori Gcv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kori Gcv filed Critical Kori Gcv
Priority to BE20210007A priority Critical patent/BE1029004B1/en
Publication of BE1029004A1 publication Critical patent/BE1029004A1/en
Application granted granted Critical
Publication of BE1029004B1 publication Critical patent/BE1029004B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Er zijn farmaceutische formuleringen ontwikkeld, die bevatten verschillende eenvoudig metabolieten, om de biologisch activiteit van glucosamine, als metaboliet, preventief of therapeutisch optimaal te gebruiken bij degeneratieve aandoeningen van het zenuwstelsel, mentale stress en burn-out. Deze farmaceutische formuleringen bezitten ook een antivirale en antitumorale werking. Virus-geïnfecteerde cellen met glucosamine formuleringen produceren niet-infectieuze virale deeltjes en virale subeenheden die, eenmaal geïsoleerd, kunnen gebruikt worden als antigenen om vaccins te ontwikkelen. De farmaceutische formuleringen bevatten D-(+)-Glucosamine hydrochloride en een of meer van de volgende stoffen: D-galactose, malaat, lactaat, acetaat, arginine, glutamine, piruvaat, propionaat, ornithine, Ringer's lactaatoplossing.Pharmaceutical formulations containing various simple metabolites have been developed to optimally utilize the biological activity of glucosamine, as a metabolite, preventively or therapeutically in degenerative disorders of the nervous system, mental stress and burnout. These pharmaceutical formulations also possess antiviral and antitumor activity. Virus-infected cells with glucosamine formulations produce non-infectious viral particles and viral subunits that, once isolated, can be used as antigens to develop vaccines. The pharmaceutical formulations contain D-(+)-Glucosamine hydrochloride and one or more of the following: D-galactose, malate, lactate, acetate, arginine, glutamine, piruvate, propionate, ornithine, lactated Ringer's solution.

BE20210007A 2021-01-11 2021-01-11 New pharmaceutical formulations, based on simple metabolites, for use in degenerative disorders of the nervous system, in viral infections and in tumor diseases BE1029004B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BE20210007A BE1029004B1 (en) 2021-01-11 2021-01-11 New pharmaceutical formulations, based on simple metabolites, for use in degenerative disorders of the nervous system, in viral infections and in tumor diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BE20210007A BE1029004B1 (en) 2021-01-11 2021-01-11 New pharmaceutical formulations, based on simple metabolites, for use in degenerative disorders of the nervous system, in viral infections and in tumor diseases

Publications (2)

Publication Number Publication Date
BE1029004A1 BE1029004A1 (en) 2022-08-08
BE1029004B1 true BE1029004B1 (en) 2022-08-16

Family

ID=78819201

Family Applications (1)

Application Number Title Priority Date Filing Date
BE20210007A BE1029004B1 (en) 2021-01-11 2021-01-11 New pharmaceutical formulations, based on simple metabolites, for use in degenerative disorders of the nervous system, in viral infections and in tumor diseases

Country Status (1)

Country Link
BE (1) BE1029004B1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100291240A1 (en) * 2009-05-13 2010-11-18 Wyeth Llc Method to Stabilize a Dietary Supplement to Facilitate Joint Health in Humans

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100291240A1 (en) * 2009-05-13 2010-11-18 Wyeth Llc Method to Stabilize a Dietary Supplement to Facilitate Joint Health in Humans

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ABI ADEBOWALE ET AL: "The bioavailability and pharmacokinetics of glucosamine hydrochloride and low molecular weight chondroitin sulfate after single and multiple doses to beagle dogs", BIOPHARMACEUTICS AND DRUG DISPOSITION., vol. 23, no. 6, 1 January 2002 (2002-01-01), US, pages 217 - 225, XP055579848, ISSN: 0142-2782, DOI: 10.1002/bdd.315 *
DALIRFARDOUEI RAZIEH ET AL: "Molecular mechanisms and biomedical applications of glucosamine as a potential multifunctional therapeutic agent", LIFE SCIENCE, PERGAMON PRESS, OXFORD, GB, vol. 152, 21 March 2016 (2016-03-21), pages 21 - 29, XP029536292, ISSN: 0024-3205, DOI: 10.1016/J.LFS.2016.03.028 *

Also Published As

Publication number Publication date
BE1029004A1 (en) 2022-08-08

Similar Documents

Publication Publication Date Title
Abu Eid et al. Enhanced therapeutic efficacy and memory of tumor-specific CD8 T cells by ex vivo PI3K-δ inhibition
Michaeloudes et al. Role of metabolic reprogramming in pulmonary innate immunity and its impact on lung diseases
Holvast et al. Influenza vaccination in systemic lupus erythematosus: safe and protective?
Olatunya et al. Preliminary trial of Aloe vera gruel on HIV infection
WO2019144126A8 (en) Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells
Song et al. S-adenosylmethionine (AdoMet) modulates endotoxin stimulated interleukin-10 production in monocytes
Zhamanbaeva et al. Antitumor activity of ethanol extract from Hippophae rhamnoides L. leaves towards human acute myeloid leukemia cells in vitro
BE1029004B1 (en) New pharmaceutical formulations, based on simple metabolites, for use in degenerative disorders of the nervous system, in viral infections and in tumor diseases
Cuthbertson et al. Purinergic signalling in allogeneic haematopoietic stem cell transplantation and graft-versus-host disease
Ou et al. Dryocrassin ABBA, a novel active substance for use against amantadine-resistant H5N1 avian influenza virus
Smee et al. Anti‐cowpox Virus Activities of Certain Adenosine Analogs, Arabinofuranosyl Nucleosides, and 2′‐Fluoro‐arabinofuranosyl Nucleosides
Hallstrand et al. Function of the airway epithelium in asthma
Gourin et al. Anti-CMV therapy, what next? A systematic review
Haruki et al. Indoleamine 2, 3-dioxygenase 1 in corneal endothelial cells limits herpes simplex virus type 1-induced acquired immune response
Liu et al. Low dosages: new chemotherapeutic weapons on the battlefield of immune-related disease
Kumari et al. Withaferin A protects against primary and recurrent tuberculosis by modulating Mycobacterium-specific host immune responses
Abramets et al. Researches of the imidazole and indole derivatives cerebroprotective activity and its impact on effects of antidepressants
Osidak et al. Efficacy of the Inosine pranobex molecule in therapeutic and pediatric practice
Zhuo et al. Identification of a Self-Assembling Small-Molecule Cancer Vaccine Adjuvant with an Improved Toxicity Profile
Xilin et al. Modulation of natural killer cell activity in the setting of oncolytic virotherapy and with a chimeric antigen receptor
Sokolova et al. The effect of Kagocel® on gene expression of Toll-like receptors of innate immunity in THP-1 human monocytes with different levels of differentiation
Pietrobon et al. Antiviral response induced by toll-like receptor (TLR) 7/TLR8 activation inhibits human immunodeficiency virus type 1 infection in cord blood macrophages
Agrawal et al. Biobran/MGN-3, an Arabinoxylan Rice Bran, Exerts Anti-COVID-19 Effects and Boosts Immunity in Human Subjects. Nutrients 2024, 16, 881
Saxena et al. 3170–TRACKING DEVELOPMENT OF RUNX1+ HEMOGENIC ENDOTHELIUM IN VITRO
BR112022011834A2 (en) PYRIMIDINE DERIVATIVE AND USE THEREOF

Legal Events

Date Code Title Description
FG Patent granted

Effective date: 20220816

MM Lapsed because of non-payment of the annual fee

Effective date: 20230131